Salem Investment Counselors
ABCL icon

Salem Investment Counselors’s AbCellera Biologics ABCL Stock Holding History

Salem Investment Counselors’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,550
Closed -$53.3K – 1215
2025
Q2 		$53.3K Sell
15,550
-63,250
-80% -$157K ﹤0.01% 574
2025
Q1 		$176K Buy
78,800
+5,150
+7% +$14.8K 0.01% 374
2024
Q4 		$216K Sell
73,650
-117,500
-61% -$327K 0.01% 352
2024
Q3 		$497K Buy
191,150
+128,150
+203% +$355K 0.02% 271
2024
Q2 		$186K Buy
+63,000
New +$238K 0.01% 366

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
ArrowMark Colorado Holdings
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Salem Investment Counselors's ABCL Position: Q3 2025 in Review

Salem Investment Counselors sold out of AbCellera Biologics (ABCL) in Q3 2025, closing a stake of 15,550 shares — an estimated $53.3K sold.

Salem Investment Counselors first reported a position in ABCL in Q2 2024 and held it in 5 quarters. The position peaked at $497K in Q3 2024. 141 funds tracked by Wall St. Rank hold ABCL as of Q3 2025.

  • Salem Investment Counselors reported no remaining AbCellera Biologics position as of Q3 2025 after selling out during the quarter.
  • Salem Investment Counselors sold 15,550 AbCellera Biologics shares in Q3 2025, an estimated $53.3K.
  • Salem Investment Counselors first reported a position in AbCellera Biologics in Q2 2024 and held it in 5 quarters.
  • Salem Investment Counselors's AbCellera Biologics position peaked at $497K in Q3 2024.
  • 141 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2025.

Based on Salem Investment Counselors's 13F filing for Q3 2025, filed 7 Oct 2025.